Marshall Wace
BIOA

Marshall Wace’s BioAge Labs BIOA Stock Holding History

Marshall Wace’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$778K Sell
31,743
-158,729
-83% -$2.87M ﹤0.01% 2324
2026
Q1 		$3.33M Sell
190,472
-32,476
-15% -$625K ﹤0.01% 1515
2025
Q4 		$2.95M Buy
222,948
+48,752
+28% +$432K ﹤0.01% 1397
2025
Q3 		$1.02M Sell
174,196
-52,593
-23% -$246K ﹤0.01% 1932
2025
Q2 		$937K Buy
226,789
+173,388
+325% +$699K ﹤0.01% 1884
2025
Q1 		$201K Buy
+53,401
New +$247K ﹤0.01% 2405
2024
Q4 		– Sell
-200,000
Closed -$4.16M – 3082
2024
Q3 		$4.16M Buy
+200,000
New +$4.01M 0.01% 1066

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Marshall Wace's BIOA Position: Q2 2026 in Review

Marshall Wace reduced its BioAge Labs (BIOA) stake by 83% in Q2 2026, selling an estimated $2.87M and leaving 31,743 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

Marshall Wace first reported a position in BIOA in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.16M in Q3 2024. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Marshall Wace held 31,743 shares of BioAge Labs worth $778K as of Q2 2026.
  • Marshall Wace sold 158,729 BioAge Labs shares in Q2 2026, an estimated $2.87M.
  • BioAge Labs made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2324 holding.
  • Marshall Wace first reported a position in BioAge Labs in Q3 2024 and has held it in 7 quarters since.
  • Marshall Wace's BioAge Labs position peaked at $4.16M in Q3 2024.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.